Among several reported studies in colorectal cancer, lung cancer, and ovarian cancer patients, a tumor-specific p53 mutation was detected in an average of 40%, 75%, and 26%, respectively, of the corresponding plasma samples (Table 3, Table S6). This evidence concerns the gene TP53 and lung cancer.